{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06500273",
            "orgStudyIdInfo": {
                "id": "ALLO-501A-202"
            },
            "organization": {
                "fullName": "Allogene Therapeutics",
                "class": "INDUSTRY"
            },
            "briefTitle": "Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL",
            "officialTitle": "A Randomized, Open-label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants With Minimal Residual Disease After Response to First Line Therapy for Large B-cell Lymphoma",
            "acronym": "ALPHA3",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "consolidation-of-first-line-mrd-remission-with-cema-cel-in-patients-with-lbcl"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-06-18",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-08-24",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2031-08-24",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-06-26",
            "studyFirstSubmitQcDate": "2024-07-11",
            "studyFirstPostDateStruct": {
                "date": "2024-07-15",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-11",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-15",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Allogene Therapeutics",
                "class": "INDUSTRY"
            },
            "collaborators": [
                {
                    "name": "Foresight Diagnostics, Inc.",
                    "class": "UNKNOWN"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": true,
            "isUnapprovedDevice": true
        },
        "descriptionModule": {
            "briefSummary": "This is a randomized, open-label study in adult patients who have completed standard first line of therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have minimal residual disease (MRD) as detected by the Foresight CLARITY\u2122 Investigational Use Only (IUO) MRD test, powered by PhasED-Seq\u2122. The purpose of the trial is to assess the efficacy and safety of consolidation with cemacabtagene ansegedleucel (cema-cel), an allogeneic CD19 CAR T product, as compared to standard of care observation.\n\nThe study is conducted in 2 consecutive parts that will be enrolled continuously. In Part A of the study, participants with MRD are randomized to one of two treatment arms or an observation arm. Treatment includes cema-cel following a lymphodepletion regimen of fludarabine and cyclophosphamide administered with or without the anti-CD52 monoclonal antibody, ALLO-647. Part A will culminate with the selection of the lymphodepletion regimen to advance to Part B. Part B will evaluate the selected lymphodepletion regimen followed by cema-cel as compared with observation."
        },
        "conditionsModule": {
            "conditions": [
                "Large B-cell Lymphoma"
            ],
            "keywords": [
                "Diffuse large B-cell lymphoma",
                "DLBCL",
                "Primary mediastinal B-cell lymphoma",
                "LBCL",
                "High grade B-cell lymphoma",
                "HGBCL",
                "Double-hit lymphoma",
                "High-risk lymphoma",
                "Minimal Residual Disease",
                "MRD",
                "CAR T",
                "Allogeneic CAR T",
                "CD19",
                "cema-cel",
                "cemacabtagene ansegedleucel",
                "ALLO-647",
                "PMBCL",
                "Consolidation",
                "First-line",
                "Front-line",
                "Frontline",
                "PhasED-Seq\u2122",
                "CLARITY\u2122",
                "Anti-CD52",
                "AlloCAR T\u2122"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 250,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "cemacabtagene ansegedleucel, ALLO-647",
                    "type": "EXPERIMENTAL",
                    "description": "Participants receive cemacabtagene ansegedleucel following lymphodepletion regimen comprised of fludarabine, cyclophosphamide, and ALLO-647.",
                    "interventionNames": [
                        "Genetic: cemacabtagene ansegedleucel",
                        "Biological: ALLO-647",
                        "Drug: Fludarabine",
                        "Drug: Cyclophosphamide",
                        "Device: Foresight CLARITY\u2122 IUO MRD test, powered by PhasED-Seq\u2122"
                    ]
                },
                {
                    "label": "cemacabtagene ansegedleucel",
                    "type": "EXPERIMENTAL",
                    "description": "Participants receive cemacabtagene ansegedleucel following lymphodepletion regimen comprised of fludarabine and cyclophosphamide.",
                    "interventionNames": [
                        "Genetic: cemacabtagene ansegedleucel",
                        "Drug: Fludarabine",
                        "Drug: Cyclophosphamide",
                        "Device: Foresight CLARITY\u2122 IUO MRD test, powered by PhasED-Seq\u2122"
                    ]
                },
                {
                    "label": "Observation",
                    "type": "OTHER",
                    "description": "Participants do not receive any study treatments. They are observed as per the current standard of care.",
                    "interventionNames": [
                        "Device: Foresight CLARITY\u2122 IUO MRD test, powered by PhasED-Seq\u2122"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "GENETIC",
                    "name": "cemacabtagene ansegedleucel",
                    "description": "An allogeneic CAR T cell therapy targeting CD19",
                    "armGroupLabels": [
                        "cemacabtagene ansegedleucel",
                        "cemacabtagene ansegedleucel, ALLO-647"
                    ],
                    "otherNames": [
                        "cema-cel"
                    ]
                },
                {
                    "type": "BIOLOGICAL",
                    "name": "ALLO-647",
                    "description": "A monoclonal antibody targeting CD52",
                    "armGroupLabels": [
                        "cemacabtagene ansegedleucel, ALLO-647"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Fludarabine",
                    "description": "Chemotherapy for lymphodepletion",
                    "armGroupLabels": [
                        "cemacabtagene ansegedleucel",
                        "cemacabtagene ansegedleucel, ALLO-647"
                    ],
                    "otherNames": [
                        "Fludara\u00ae"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Cyclophosphamide",
                    "description": "Chemotherapy for lymphodepletion",
                    "armGroupLabels": [
                        "cemacabtagene ansegedleucel",
                        "cemacabtagene ansegedleucel, ALLO-647"
                    ],
                    "otherNames": [
                        "Cytoxan\u00ae"
                    ]
                },
                {
                    "type": "DEVICE",
                    "name": "Foresight CLARITY\u2122 IUO MRD test, powered by PhasED-Seq\u2122",
                    "description": "A diagnostic test intended to identify patients with minimal residual disease at the end of first line treatment for lLBCL.",
                    "armGroupLabels": [
                        "Observation",
                        "cemacabtagene ansegedleucel",
                        "cemacabtagene ansegedleucel, ALLO-647"
                    ],
                    "otherNames": [
                        "Foresight Lymphoma MRD Therapy Selection Test"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Event-free survival per independent review committee assessment",
                    "timeFrame": "Up to 60 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Progression-free survival per independent review committee assessment",
                    "timeFrame": "Up to 60 months"
                },
                {
                    "measure": "Overall survival",
                    "timeFrame": "Up to 60 months"
                },
                {
                    "measure": "Incidence and severity of adverse events and their relationship to cemacabtagene ansegedleucel and ALLO-647",
                    "description": "Adverse events, treatment emergent adverse events, serious adverse events, and adverse events of special interest evaluated by the investigator based on the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. CRS and ICANS will be graded using ASTCT.",
                    "timeFrame": "Up to 60 months"
                },
                {
                    "measure": "Incidence and severity of laboratory toxicities related to cemacabtagene ansegedleucel and ALLO-647",
                    "description": "Change from baseline value and NCI toxicity grading of laboratory values outside of normal ranges using CTCAE version 5.0.",
                    "timeFrame": "Up to 60 months"
                },
                {
                    "measure": "Minimal residual disease clearance",
                    "timeFrame": "Up to 60 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Key Inclusion Criteria:\n\n1. LBCL per WHO 2017 including diffuse large B-cell lymphoma, high-grade B-cell lymphoma, and primary mediastinal B-cell lymphoma histologically confirmed by pathology report.\n2. Participant has completed a full course of standard first line therapy (e.g., R-CHOP, dose-adjusted EPOCH-R, Pola-R-CHP) as intended. Participants cannot have received additional lines of therapy.\n3. Participant achieved CR, or PR suitable for observation at the end of first line therapy based on PET/CT evaluation\n4. Foresight CLARITY\u2122 IUO MRD test, powered by PhasED-Seq\u2122, is positive.\n5. Adult participants \u226518 years of age.\n6. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.\n7. Adequate hematological, renal, hepatic, pulmonary, and cardiac function\n8. Non-hematologic toxicities related to prior therapy must be recovered to baseline or grade \u22641.\n\nKey Exclusion Criteria:\n\n1. LBCL with history of central nervous system involvement, transformed from other malignancy (e.g., transformed follicular lymphoma or marginal zone lymphoma, Richter's transformation), or T-cell/histiocyte rich LBCL.\n2. Prior treatment with anti-CD19 targeted therapies.\n3. Anti-cancer treatment, including radiation, after end of treatment PET/CT and/or MRD testing is performed.\n4. Active and clinically significant autoimmune disease.\n5. Active systemic bacterial, fungal, or viral infections requiring systemic treatment (e.g., HIV).\n6. History of another primary malignancy or bone marrow disorder (e.g., myelofibrosis, smoldering multiple myeloma) within 3 years prior to enrollment.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Allogene Therapeutics, Inc",
                    "role": "CONTACT",
                    "phone": "+1 415-604-5696",
                    "email": "clinicaltrials@allogene.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Allogene Study Director",
                    "affiliation": "Allogene Therapeutics, Inc.",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Rocky Mountain Cancer Centers",
                    "status": "RECRUITING",
                    "city": "Denver",
                    "state": "Colorado",
                    "zip": "80218",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "John Burke",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.73915,
                        "lon": -104.9847
                    }
                },
                {
                    "facility": "Norton Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Louisville",
                    "state": "Kentucky",
                    "zip": "40207",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Don Stevens",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.25424,
                        "lon": -85.75941
                    }
                },
                {
                    "facility": "Astera Cancer Care",
                    "status": "RECRUITING",
                    "city": "East Brunswick",
                    "state": "New Jersey",
                    "zip": "08816",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Edward Licitra",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.42788,
                        "lon": -74.41598
                    }
                },
                {
                    "facility": "Oncology Associates of Oregon",
                    "status": "RECRUITING",
                    "city": "Eugene",
                    "state": "Oregon",
                    "zip": "97401",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Jeff Sharman",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 44.05207,
                        "lon": -123.08675
                    }
                },
                {
                    "facility": "Texas Oncology - Longview Cancer Center",
                    "status": "RECRUITING",
                    "city": "Longview",
                    "state": "Texas",
                    "zip": "75601",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Habte Yimer",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.5007,
                        "lon": -94.74049
                    }
                },
                {
                    "facility": "Virginia Cancer Specialists",
                    "status": "RECRUITING",
                    "city": "Fairfax",
                    "state": "Virginia",
                    "zip": "22031",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Mitul Gandhi",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.84622,
                        "lon": -77.30637
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008223",
                    "term": "Lymphoma"
                },
                {
                    "id": "D000016393",
                    "term": "Lymphoma, B-Cell"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000008232",
                    "term": "Lymphoproliferative Disorders"
                },
                {
                    "id": "D000008206",
                    "term": "Lymphatic Diseases"
                },
                {
                    "id": "D000007160",
                    "term": "Immunoproliferative Disorders"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                },
                {
                    "id": "D000008228",
                    "term": "Lymphoma, Non-Hodgkin"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M11220",
                    "name": "Lymphoma",
                    "asFound": "Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M18828",
                    "name": "Lymphoma, B-Cell",
                    "asFound": "B-cell Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M18831",
                    "name": "Lymphoma, Large B-Cell, Diffuse",
                    "relevance": "LOW"
                },
                {
                    "id": "M20497",
                    "name": "Neoplasm, Residual",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M11225",
                    "name": "Lymphoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M11203",
                    "name": "Lymphatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10206",
                    "name": "Immunoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M11222",
                    "name": "Lymphoma, Non-Hodgkin",
                    "relevance": "LOW"
                },
                {
                    "id": "T3543",
                    "name": "Lymphosarcoma",
                    "asFound": "Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "T640",
                    "name": "B-cell Lymphoma",
                    "asFound": "B-cell Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "T1866",
                    "name": "Diffuse Large B-Cell Lymphoma",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000003520",
                    "term": "Cyclophosphamide"
                },
                {
                    "id": "C000024352",
                    "term": "Fludarabine"
                }
            ],
            "ancestors": [
                {
                    "id": "D000007166",
                    "term": "Immunosuppressive Agents"
                },
                {
                    "id": "D000007155",
                    "term": "Immunologic Factors"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000018501",
                    "term": "Antirheumatic Agents"
                },
                {
                    "id": "D000018906",
                    "term": "Antineoplastic Agents, Alkylating"
                },
                {
                    "id": "D000000477",
                    "term": "Alkylating Agents"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000019653",
                    "term": "Myeloablative Agonists"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M6727",
                    "name": "Cyclophosphamide",
                    "asFound": "Effect of",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4225",
                    "name": "Antibodies",
                    "relevance": "LOW"
                },
                {
                    "id": "M10184",
                    "name": "Immunoglobulins",
                    "relevance": "LOW"
                },
                {
                    "id": "M4230",
                    "name": "Antibodies, Monoclonal",
                    "relevance": "LOW"
                },
                {
                    "id": "M283230",
                    "name": "Fludarabine",
                    "asFound": "Rate",
                    "relevance": "HIGH"
                },
                {
                    "id": "M225513",
                    "name": "Fludarabine phosphate",
                    "relevance": "LOW"
                },
                {
                    "id": "M10212",
                    "name": "Immunosuppressive Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M10201",
                    "name": "Immunologic Factors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20604",
                    "name": "Antirheumatic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M20942",
                    "name": "Antineoplastic Agents, Alkylating",
                    "relevance": "LOW"
                },
                {
                    "id": "M3820",
                    "name": "Alkylating Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "ARhu",
                    "name": "Antirheumatic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}